Please login to the form below

Not currently logged in
Email:
Password:

Acquisition

This page shows the latest Acquisition news and features for those working in and with pharma, biotech and healthcare.

Gilead agrees $21bn buyout of Immunomedics

Gilead agrees $21bn buyout of Immunomedics

Following the acquisition, Gilead gains rights to Immunomedics antibody-drug conjugate (ADC) Trodelvy (sacituzumab govitecan-hziy), which was approved by the US Food and Drug Administration (FDA) in April for the ... This acquisition represents

Latest news

More from news
Approximately 198 fully matching, plus 1,210 partially matching documents found.

Latest Intelligence

  • AI: the smart money is on the smart thinking AI: the smart money is on the smart thinking

    Recognising this, big pharma firms are already looking to consolidate with AI solutions, if not through acquisitions, then through partnerships. ... Indeed, this has been evidenced recently by Thermo Fisher’s acquisition of Qiagen in May for $11.5bn.

  • Gut instincts lead Takeda to GI pipeline success Gut instincts lead Takeda to GI pipeline success

    Parikh has good reason to celebrate, as he has been involved in constructing a potent GI unit that took its first steps with Takeda’s 2008 acquisition of US biotechnology company ... We are completely focused on helping them.”. The GI building

  • The impact of COVID-19 on clinical trials The impact of COVID-19 on clinical trials

    Many with promising and potentially high-value platforms may be at risk of acquisition from larger companies based on unfavourable terms. ... Acquisitions might present the opportunity for larger companies to expand their pipelines with additional assets

  • Pharma funding and M&A in 2020 Pharma funding and M&A in 2020

    traditional pharmaceutical companies look to increase innovation is through bolt-on acquisitions of more innovative players in the industry. ... But such bolt-on acquisitions are not just beneficial to Big Pharma – they can also benefit smaller firms.

  • 20 for 2020 – Five pharma leaders to watch in 2020 20 for 2020 – Five pharma leaders to watch in 2020

    That new strategy was thrown into relief by Sanofi’s acquisition of cancer specialist Synthorx, announced in December 2019 and completed in January 2020, the first major deal under Hudson’s

More from intelligence
Approximately 74 fully matching, plus 89 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 119 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 9 fully matching, plus 71 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...

Infographics